# Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension

> **NCT00783094** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 422 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Tadalafil 2.5 mg
- **DRUG:** Tadalafil 5 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00783094
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-06
- **Final completion:** 2010-04
- **Target enrollment:** 422 (ACTUAL)
- **Last updated:** 2011-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783094, "Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00783094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*